Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Union Pacific Corporation (UNP) Price & Performance

BIO-TECHNE CorpTrade
Union Pacific CorporationTrade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Union Pacific Corporation — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Union Pacific Corporation trades at $293.9 (market cap $175.89B). The key difference: Union Pacific Corporation is far larger — about 15.8× BIO-TECHNE Corp's market cap, and Union Pacific Corporation pays the higher dividend (1.86%). Which is the better fit depends on your goals.

TECHUNP
Market Cap
$11.16B$175.89B
Sector
HealthIndustrials
52-Week High
$72.12$301.75
52-Week Low
$43.31$214.91
Enterprise Value
$11.24B$206.36B
Dividend Yield
0.45%1.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.

The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.

Union Pacific Corporation

Union Pacific (UNP) trades at $293.13, down 2.86% on the day, with technical indicators showing a bullish trend but overbought RSI levels. The company maintains strong profitability with a 29.2% net margin and 40.69% ROE, supported by consistent cash flow from operations of $9.29B in 2025. Recent news highlights Q2 2026 earnings anticipation and progress on the proposed Norfolk Southern merger, while a class action lawsuit presents a legal overhang.

Outlook remains positive with analyst consensus pointing to 6% upside to a $311.07 price target, though regulatory hurdles for the merger and economic sensitivity pose risks. The stock offers a solid dividend yield and operational resilience, but investors should weigh earnings performance against valuation multiples above industry averages.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH

About Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.

Read more on UNP